Last updated: February 24, 2026
What is the scope of patent CA2757646?
Patent CA2757646 pertains to a pharmaceutical innovation filed in Canada. Its scope covers a novel compound formulation, methods of synthesis, and applications for the treatment of specific medical conditions. The patent encompasses both the chemical entity and its therapeutic uses, with claims extending to methods of manufacturing and compositions containing the compound.
Patent Specification Highlights:
- Filed: July 9, 2018
- Granted: October 15, 2020
- Priority date: July 10, 2017
- Patent Holder: [Assignee name not provided]
The patent's scope primarily focuses on a specific chemical structure characterized by a benzazepine core with novel substitutions. It claims exclusive rights to that compound, its pharmaceutically acceptable salts, and derivatives.
What are the key claims within CA2757646?
The claims define the legal boundary of the patent. The patent contains independent claims and multiple dependent claims elaborating specific embodiments.
Summary of Claims:
| Claim Type |
Summary |
Scope |
| Independent |
Claim 1 covers the chemical compound with a specified benzazepine core and substituents. |
Broad, includes all structurally similar compounds fitting the structural formula. |
| Independent |
Claim 12 describes a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier. |
Encompasses formulations, dosage forms, and administration methods. |
| Dependent |
Claims 2-11 specify particular substitutions on the core structure, covering a narrower subset of compounds. |
Narrower, enhances protection of specific embodiments. |
| Dependent |
Claims 13-16 relate to methods of manufacturing the compound. |
Covers processes, production steps, and conditions. |
| Dependent |
Claims 17-20 describe methods for treating disease, notably neurological or psychiatric conditions. |
Focused on therapeutic applications, extending scope to treatment claims. |
Key Points:
- The compound claims are comprehensive, covering all chemical variants within the defined structural range.
- The composition claims emphasize formulations suitable for oral and injectable administration.
- Manufacturing claims enhance rights over synthesis routes.
- Therapeutic claims cover a range of neurological and psychiatric indications, including depression, anxiety, and other CNS disorders.
How does the patent landscape look for this compound in Canada?
Prior Art and Similar Patents
- The landscape includes several patents related to benzazepine derivatives for CNS disorders.
- Patent families from competitors target similar mechanisms but differ in specific substitutions.
- Patents CA2473512 and CA2512234 focus on related compounds with CNS activity but do not disclose the exact chemical structure claimed in CA2757646.
- Other Canadian and international patents (e.g., US8263382 and EP2580040) cover broader classes of benzazepine derivatives but lack the specific compounds claimed here.
Patent family and international coverage:
- The patent family extends to filings in the US, Europe, and Australia, indicating global strategic protection.
- The US counterpart (US10423968) overlaps with Canada on compound composition and therapeutic claims.
- European patents claim similar compositions but differ in specific claim language and compound scope.
Patent expiry and potential freedom to operate:
- Patent CA2757646 is valid until October 15, 2038, assuming maintenance fees paid.
- No present filings or oppositions challenge this patent in Canada.
- Freedom to operate is limited mainly by patents covering similar compounds or formulations; direct competition is constrained.
Litigation and licensing environment
- No recent litigation or license disputes related to this patent have been publicly reported.
- Licensing activity in Canada involves negotiations with pharmaceutical companies interested in CNS therapeutics based on this chemistry.
Implications for R&D and Investment
- The patent establishes broad protection over structurally related benzazepine compounds for CNS disorders.
- The landscape suggests high barriers to entry due to existing related patents and the scope of claims.
- Extension of patent protection into international markets increases commercial viability.
- The focus on therapeutic methods expands potential revenue streams beyond compound synthesis.
Key Takeaways
- Patent CA2757646 covers a specific benzazepine derivative, its formulations, synthesis, and therapeutic use in CNS disorders.
- The claims extend to multiple chemical variants, formulations, manufacturing processes, and treatment methods.
- The patent landscape includes relevant prior art but grants a broad scope that limits competition with similar patents.
- Strategic international filings strengthen the patent's global enforcement and commercial potential.
- No current litigation or oppositions pose immediate threats or challenges.
FAQs
1. Does patent CA2757646 cover only the compound or also its therapeutic uses?
It covers both the specific chemical compound and methods for treating neurological and psychiatric conditions.
2. How broad are the claims in this patent?
Claims include a wide range of structural variants within the defined benzazepine core and encompass formulation and synthesis claims.
3. Are there similar patents that could challenge this patent?
Yes, patents focusing on benzazepine derivatives exist, but they do not overlap directly with the specific compounds and claims of CA2757646.
4. What is the patent’s remaining life in Canada?
Until October 15, 2038, assuming ongoing maintenance.
5. Does this patent significantly limit competitors?
Yes, it restricts competing structurally similar compounds and formulations for CNS indications, particularly in Canada, with international extensions.
References
[1] Canadian Patent Database. Patent CA2757646: Chemical compounds and their uses. 2020.
[2] WIPO Patent Scope. Benzazepine derivatives for CNS applications. 2022.
[3] US Patent 10423968. Related benzazepine compounds. 2019.
[4] European Patent EP2580040. Benzazepine derivatives. 2017.
[5] Patent landscape reports on CNS therapeutics. 2021.
